Background. Pneumococcal conjugate vaccines (PCVs) provide direct protection against disease in those vaccinated, and interrupt transmission through the prevention of nasopharyngeal (NP) carriage.
Vaccination with pneumococcal conjugate vaccines (PCV) induces immunoglobulin G (IgG) antibody production, which peaks approximately 1 month after vaccination and wanes thereafter in the absence of serotype-specific exposures [1] . The concentration of circulating serum antibody that is sufficient to protect an infant against invasive pneumococcal disease (IPD) or nasopharyngeal (NP) colonization during the postvaccination period is not well defined, but is generally higher for mucosal endpoints than IPD and varies between serotypes [2] [3] [4] .
In large efficacy trials, only a small proportion of children will have antibody concentrations assessed after vaccination, precluding analyses that directly link the antibody concentration in an individual with his or her disease outcome. In such situations, the overall trial-level estimates of the proportion with disease and the proportions with antibody below a threshold level are used to define an antibody level associated with protection, which is referred to as a correlate of protection [5] [6] [7] . A pooled correlate of protection against IPD of 0.35 µg/mL was derived from a meta-analysis of 3 efficacy trials [6, [8] [9] [10] . Although these thresholds have provided a means to establish licensure of additional products, they cannot predict protection for the individual, as evidenced by a case report of vaccine failure in a 9-month-old child, 10 days after a measured antibody concentration of 4.98 µg/mL [11] .
Current correlates of protection refer only to protection against IPD, and not to other endpoints of clinical importance such as acute otitis media or nonbacteremic pneumonia, nor to NP carriage. The effector molecule for protection against mucosal colonization is unlikely to be circulating serum IgG, but instead may be IgG or immunoglobulin A (IgA) that is produced by mucosally associated B cells, or IgG that leaks from circulation to mucosa [12, 13] . Nevertheless, circulating serum IgG concentrations measured 4-6 weeks after vaccination can serve as a proxy for the level of immune response to PCVs, which in turn provides protection from carriage. Because NP colonization is a necessary precondition for development of pneumococcal disease and is the mechanism for transmission of pneumococcal infection, vaccine efficacy against this endpoint is key to preventing disease, reducing transmission, inducing herd immunity, and thereby delivering maximum health benefits of PCV [14, 15] .
The aim of this study was to use a large number of vaccine trials with individual participant-level data to calculate the concentration of serotype-specific serum IgG, which is associated with protection against NP colonization in the individual.
METHODS

Data
Individual-level serological data were sought from immunogenicity clinical trials in which PCV was administered to children in prime-boost schedules. Blood samples were taken for serology at 1 month postpriming and at the booster dose visit. For each participant, antibody concentrations were compared at the 1-month postpriming visit and the booster visit. Any increase in antibody at the latter time point was considered evidence for natural boosting due to pneumococcal carriage acquisition at some point in the intervening period ("seroincidence").
Randomized Trial in Nepal
Additional immunogenicity data were available from an open-label, randomized controlled trial of 10-valent PCV in Nepal (authors' own data). Details of the trial have been previously published [16] (Supplementary Materials).
Antibody concentrations have been shown to increase after NP carriage [17] . To confirm that any increase in antibody between 2 time points is a good proxy measure for NP colonization with the same serotype, antibody data from the Nepal randomized controlled trial were paired with data from a crosssectional carriage study of 600 healthy children (aged 6 weeks to 24 months) conducted during the same period and at the same study center [18] . High correlation between the proportions of children with an increase in antibody levels and the proportions of community children with positive NP swabs, was considered supportive evidence for the use of seroincidence as a marker of NP carriage.
Use of Carriage Seroincidence to Define Antibody Thresholds of Protection
Two methods were used to analyze the association between serotype-specific pneumococcal serum antibody concentrations and seroincidence.
First, serotype-specific receiver operating characteristic (ROC) curves were created for antibody measured 1 month postpriming vaccination, compared with seroincidence in the following months prior to the booster dose visit (Supplementary Table 1 and Supplementary Figure 1) . From each ROC curve, the antibody level that maximized the sum of sensitivity plus specificity was retained as the antibody level most able to discriminate between those with and without presumed carriage acquisition in the postvaccination period [19, 20] .
A second analysis used generalized additive models (GAMs) to compute the protective efficacy of the antibody thresholds identified from ROC curves. A GAM model for binary data using seroincidence as the outcome was applied to each country cohort and serotype separately, with IgG at 1 month postpriming fitted with a spline smooth. The models were adjusted for age and sex. For each country cohort, the antibody concentration at which the probability of seroincidence became negligible (probability < .05) was identified.
The probability of seroincidence at the level of antibody identified from the ROC curves was compared to the probability of seroincidence in those with antibody below the lower limit of assay quantification to compute the protective efficacy of each ROC threshold.
Protective thresholds from the ROC curves were compared across income strata (high/upper middle-income countries [H/ UMICs] vs low/lower middle-income countries [L/LMICs]) using mixed-effects models. In addition, the proportion of infants with maternal antibody prior to vaccination was compared. Infants with antibody against pneumococcal serotypes prior to vaccination are likely indicative of mothers who had been susceptible, exposed, and infected (likely with asymptomatic carriage) within a time period that enabled transplacental transfer of antibody to occur. The seroprevalence of type-specific pneumococcal antibodies in infants aged approximately 8 weeks is therefore interpreted as a surrogate measure of the force of infection and its association with calculated ROC antibody thresholds was investigated.
Sensitivity analyses were undertaken as detailed in the Supplementary Materials, which contain further statistical methods.
RESULTS
Antibody Increase and Circulating Serotypes in the Community
There was a strong relationship (R 2 = 0.743) between seroincidence in the immunogenicity trial participants in Nepal, and NP carriage prevalence among children in the same community as the trial participants. Because antibodies to some serotypes are cross-reactive to other serotypes within the same serogroup (vaccine-related types), it was unclear which serotype might be responsible for an observed antibody increase among the immunogenicity participants. For this reason, serotype data from NP carriage observations were combined into serogroups.
With the exception of serotypes 1 and 5, confidence intervals (CIs) for NP carriage included the line of best fit ( Figure 1 ).
Serotype-Specific Antibody Thresholds of Protection Against Seroincidence
Pneumococcal IgG serum concentrations were available from 29 studies (19 countries and 5224 children). Studies were conducted in Europe (Denmark, Czech Republic, Finland, France, Germany, the Netherlands, Poland, Slovakia, Spain, and Sweden), Asia (India, Japan, Malaysia, Nepal, the Philippines, and Singapore), Africa (Mali and Nigeria), and Chile (Supplementary Table 2 ). Pneumococcal antibody thresholds of protection derived from ROC curves varied by serotype. The lowest threshold was 0.50 µg/mL and the highest was 2.54 µg/mL, for pneumococcal serotypes 6B and 19F antibodies, respectively ( Figure 2 and Table 1 ).
The probability of seroincidence from GAM models declined as antibody increased, until a point where the probability became negligible and curves flattened out ( Figure 3 ). For Serotype-specific pneumococcal antibody correlates of protection against seroincidence in infancy. Circles represent serotype-specific thresholds of protection against carriage derived from receiver operating characteristic curves and 95% confidence intervals (CIs). Squares represent thresholds of protection and 95% CIs from generalized additive models. Horizontal bars are antibody correlates of protection for invasive pneumococcal disease from Andrews et al [2] (not available for serotype 5). Data are also presented in Table 1 . Abbreviations: IgG, immunoglobulin G; PCV, pneumococcal conjugate vaccine. serotype 1, the probability of seroincidence was low for all levels of postprimary antibody; thus, the point at which the probability became negligible could not be defined (Figure 3 ). For serotypes 4, 5, 7F, and 18C, the postprimary antibody thresholds from both ROC and GAM methods were essentially the same; thus, seroincidence is negligible for antibody above these levels. For the remaining serotypes (6B, 9V, 14, 19F, and 23F), antibody concentrations of at least 3.45 µg/mL were required to minimize seroincidence to the 5% level. However, substantial protection against seroincidence was available with antibody at levels of 0.50-2.54 µg/mL as defined by ROC curves, and protective efficacy estimates at these levels was between 62% and 87% (Table 1) .
High-and Low-Income Countries
Overall across all serotypes, thresholds derived from ROC curves were twice as high in L/LMICs than in H/UMICs (geometric mean ratio, 2.15 [95% CI, 1.46-3.17]; P = .0024) although, for individual serotypes, the CIs overlapped ( Figure 4) . Seroprevalence of maternal antibodies in infants prior to vaccination was also higher in L/LMICs (P = .0006), and there was a significant relationship between the proportion of children with maternal antibody and the estimated correlate of protection for the same serotypes (P = .0347) (Supplementary Figure 2) .
Sensitivity Analyses
Sensitivity analyses showed that variations in the definition of seroincidence had little impact on calculated correlates of protection (Supplementary Table 3) .
DISCUSSION
This analysis of infant immunogenicity data from 5224 infants in 29 studies in 19 countries estimates pneumococcal serotypespecific antibody concentrations associated with protection against an increase in antibody following the primary vaccination series, which we infer as a proxy for NP carriage. It confirms that more antibody is needed to protect against carriage than the current level of 0.35 mg/mL associated with protection against IPD. Dagan et al, in a study of NP carriage acquisition, reported that >80% of acquisitions occurred in children with antibody >0.35 µg/mL 1 month post-primary vaccination [4] . All calculated antibody concentrations in our study were higher than serotype-specific correlates of protection previously derived for IPD, a finding also observed by Dagan et al [2, 4] .
The mechanism of protection against carriage is unclear, but could be mediated by either IgA or IgG. IgA-mediated immunity has been demonstrated in mice, and levels of the isotype are typically lower than and proportional to systemic IgG levels [21] . However, Streptococcus pneumoniae produces an IgA protease, which may mean that local production of IgA at the mucosa is successfully evaded by pneumococci [22] . It may be that higher blood levels of IgG correlate with local production of IgG at the mucosa, or that high levels of circulating IgG leak across to the mucosal surface from the circulation and provide local protection against colonization [13] .
Relationship With Circulating Serotypes
The serogroup-specific prevalence of NP carriage in unvaccinated healthy children in a cross-sectional carriage study in Figure 2 . Protective efficacy is calculated as 1 -[pr(ROC)/pr(LLD)] × 100%, where pr(ROC) is the probability of seroincidence predicted from GAM model at a level of antibody equivalent to the ROC correlate of protection, and pr(LLD) is the probability of seroincidence predicted from GAM model at the lower limit of detection of the assay (.05 μg/mL). For serotypes 4, 5, 7F, and 18C, the ROC and GAM thresholds had substantially overlapping confidence intervals. The probability of seroincidence is considered to be the same (5%) for both methods.
Abbreviations: GAM, generalized additive model method for derivation of thresholds of protection; LCL, lower 95% confidence limit; LLD, lower limit of assay detection; NA, not analysed; PE, protective efficacy; ROC, receiver operating characteristic curve method for derivation of correlates of protection; UCL, upper 95% confidence limit. a Antibody level at which the probability of seroincidence is <5%.
b Predicted probability from GAM model.
Figure 3.
The relationship between the serotype-specific probability of seroincidence estimated from generalized additive models, and the antibody concentration measured 1 month after administration of 2 or 3 priming doses of pneumococcal conjugate vaccine. Each dot represents 1 participant; horizontal dashed lines indicate a probability of .05. Abbreviation: IgG, immunoglobulin G.
Nepal was closely associated with the proportions of children who had antibody increases in the PCV immunogenicity trial. The 2 studies were conducted in the same period and location, providing compelling, indirect evidence of the validity of using serology to infer colonization. For serotypes 1 and 5, the frequency of seroincidence was not closely associated with NP carriage prevalence in the community. There were no positive swabs for serotype 1, and only one for serotype 5 from 600 children tested, yet large proportions of children in the immunogenicity trial had antibody increases by 3 years of age for these serotypes. These serotypes appear to circulate more widely than is indicated by cross-sectional carriage studies, consistent with data showing a short half-life of colonization, and rapid transmission [23] . Serotypes 1 and 5 are associated with the majority of invasive disease cases among young children in Nepal [18, 24] ; therefore, serological methods may be better at assessing colonization for these serotypes than NP swabs.
Protective Thresholds
Substantial variation exists in the level of antibody associated with protection against carriage, as potentially expressed by seroincidence. Thresholds defined using ROC curves represent the antibody level that best distinguishes those who have greater levels of protection. Using ROC curves, the lowest correlates of protection (0.50 µg/ mL and 0.63 µg/mL) were observed for serotypes 6B and 23F, respectively, and the highest were 2.54 µg/mL and 2.48 µg/mL for serotypes 19F and 14, respectively. Andrews et al calculated correlates of protection using IPD cases in children in the United Kingdom and found similar serotype-specific variation, with higher levels of antibody required for 19F and lower levels for 6B and 23F [2] . Similarly, Dagan et al reported that the antibody level above which 10% of carriage acquisitions occurred was high for serotypes 14 and 19F and low for 23F; however, 6B was also high in that study [4] . These findings are consistent with in vitro evidence that more IgG is required to kill serotype 19F than 6B [25] .
GAM thresholds can be interpreted as the level of antibody at which the probability of seroincidence becomes negligible (<5%). For serotypes 4, 5, 7F, and 18C, the ROC and GAM thresholds were similar. For serotypes 6B, 9V, 14, 19F, and 23F, much higher levels of antibody were consistent with a probability of seroincidence of 5% than those obtained from ROC curves; thus, the ROC correlates for these serotypes indicate less than complete protection for the individual. Such difference may relate to a longer duration of carriage [26, 27] .
These antibody concentrations show similarities with thresholds derived for other mucosal endpoints. Our estimate of 0.50 µg/mL for serotype 6B derived using ROC methods had a protective efficacy of 62%. This is very similar to the predicted vaccine efficacy of ≥65% against acute otitis media at 0.5 µg/mL reported by Jokinen et al [28] . Thus, an antibody concentration of 0.5 µg/mL more than halves the probability of 6B carriage, and the majority of protection occurs with induction of this small amount of antibody. In Dagan et al's model of carriage acquisition rates, which used similar regression model methodology, 0.5 µg/mL of antibody against serotype 6B equated to approximately 6.5% probability of acquisition in the Jewish cohort, and 13.5% acquisition in the Bedouin community. Ten percent of carriage acquisitions occurred in those with postvaccination antibody of at least 7.4 µg/mL or 10.8 µg/mL in the Jewish and Bedouin cohorts, respectively [4] .
In contrast, vaccine efficacy against serotype 23F acute otitis media was negligible in Jokinen et al, at 0.65 µg/mL with wide CIs [28] , whereas in our analysis protective efficacy against colonization was 74% at this antibody level. Millar et al investigated 17 cases of serotype 23F carriage acquisition after vaccination with 7-valent PCV and reported no carriers achieving serotype 23F antibody concentrations >4 mg/mL before acquisition. This threshold value for total protection is slightly lower than the estimate from GAM analysis of 5.81 mg/mL (95% CI, 4.64-7.28 mg/mL) [29] . In the Dagan et al study, 10% of acquisitions occurred at antibody levels >2.97 mg/mL. The probability of seroincidence predicted from GAM models for serotypes 9V, 14, 19F, and 23F was between 10% and 22% for antibody at the level of the ROC thresholds. Thus these levels of antibody provide substantial protection even though not representing levels that provide absolute protection for an individual.
High-and Low-Income Countries
Protective antibody concentrations were on average twice as high in L/LMICs than in more wealthy countries. Carriage of pneumococci increases with factors such as household size, exposure to smoke (including from cooking fires), and underlying illnesses [30] [31] [32] . Such factors are also related to socioeconomic status. Higher rates of NP colonization in low-income settings have been observed from carriage studies in young children [32] and in rural compared with urban settings [31] . Dagan et al showed that the relationship between carriage acquisition rates and antibody levels can be quite different for high and low socioeconomic groups in a study of Jewish and Bedouin communities [4] . Higher rates of colonization in the community (ie, higher force of infection) would increase the probability that such colonization occurs during pregnancy, resulting in higher maternal antibody in early infancy. Seroprevalence of maternal antibodies is therefore a useful proxy for exposure. Our analysis shows the seroprevalence of maternal antibodies in infants (a surrogate for the force of infection) is higher in L/LMICs, and is significantly related to the antibody concentration required for protection against seroincidence for the same serotypes. The higher level of antibody needed for protection in L/LMICs may relate to a higher infectious load delivered at each NP exposure event, requiring higher levels of antibody for individual protection. In addition, the variation across serotypes in both force of infection and antibody levels required for protection indicates biological variation in characteristics of the bacteria, resulting in varying abilities of serotypes of pneumococci to colonize the nasopharynx.
Limitations and Strengths
Deriving robust thresholds of protection from any single study is problematic due to the large degree of variation between studies in both vaccine efficacy and estimated correlates of protection [2, 6, 8, 10] . The main strength of this analysis is therefore the uniquely large dataset of paired immunogenicity data in infants from a large number of studies. All results were assayed in one laboratory. This has the benefit of reducing the influence of interlaboratory variation, but this also means caution must be applied when extrapolating to results from other laboratories and other vaccines.
The use of seroincidence as a proxy for carriage improves the detection of acquisition events as the data are not limited by the timing and frequency of NP swabs, but instead create a historical record of the acquisition events experienced during the period between the postprimary age and the booster age. This improves the differential misclassification that affects cross-sectional carriage studies, but cannot remove it entirely. Misclassification of true carriage events in our data can be due to many reasons, including (1) rises and then falls in antibody between blood draws, resulting in an overall observed decline; or (2) rises in antibody from transient exposure but not a true carriage event. These data were not from studies designed to compute antibody thresholds and are speculative in nature. The lengths of time between priming and booster doses varied across studies, which may affect misclassification rates and the thresholds calculated from the data.
CONCLUSIONS
The variation between serotypes in antibody levels that are associated with an inferred protection against carriage in this investigation support previous observations that combined correlates of protection for all serotypes are inaccurate for some serotypes [17] .
We recommend considering the use of serotype-specific thresholds of protection in clinical trials to demonstrate induction of antibody levels associated with high protection against colonization to support vaccine development, dosing schedule optimization, and the assessment of vaccine impact.
In settings with high force of infection, often low-income settings, higher levels of antibody are required to interrupt transmission. These findings are important for global vaccination policy, especially with regard to assessment of alternative schedules aimed at reducing transmission to gain indirect effects (herd immunity) of the vaccine and maximizing the impact of the vaccine.
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